A variety of phase II clinical trials are underway to study the role of ARX-788 in HER2-positive metastatic breast cancer (NCT05018676), selected HER2-mutated or HER2-amplified solid tumors (NCT05041972), HER2-low breast cancers (NCT05018676) and HER2-positive breast cancer with brain metastasis (NCT05018702). This evidence concerns the gene ERBB2 and breast carcinoma.